VistaGen Therapeutics
VTGN
92 hedge funds and large institutions have $9.13M invested in VistaGen Therapeutics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 26 reducing their positions, and 37 closing their positions.
2,121% more call options, than puts
Call options by funds: $422K | Put options by funds: $19K
27% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 26
1.33% less ownership
Funds ownership: 2.24% → 0.91% (-1.3%)
18% less funds holding
Funds holding: 112 → 92 (-20)
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
92% less capital invested
Capital invested by funds: $110M → $9.13M (-$101M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.68M |
| 2 |
Renaissance Technologies
New York
|
+$969K |
| 3 |
State Street
Boston,
Massachusetts
|
+$574K |
| 4 |
Two Sigma Investments
New York
|
+$262K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$18.2M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$14.3M |
| 3 |
CC
Commodore Capital
New York
|
-$11.5M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$10M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$3.92M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$89 | +9 | +13% |
|
|
SSG
127
Summit Securities Group
New York
| – | +$178 | +18 | New |
|
|
CS
128
Credit Suisse
Zurich,
Switzerland
| – | +$724 | +73 | +2,433% |
|
VTGN Hedge Fund Activity: Q3 2022 in Review
92 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2022, worth a combined $9.13M — down 92% from $110M a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of VTGN and 17 opened new positions — a net loss of 20 holders — while 26 trimmed existing stakes and 33 added.
The largest buyer was GSA Capital Partners, adding an estimated $1.68M. The largest seller was VR Adviser, exiting entirely with an estimated $18.2M sold.
- 92 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2022, down from 112 in Q2 2022.
- Funds reported $9.13M of VistaGen Therapeutics stock for Q3 2022, down 92% quarter-over-quarter.
- 17 funds opened new VistaGen Therapeutics positions in Q3 2022 and 37 closed out, a net change of -20 holders.
- The largest VistaGen Therapeutics buyer in Q3 2022 was GSA Capital Partners, an estimated $1.68M added.
- The largest VistaGen Therapeutics seller in Q3 2022 was VR Adviser, an estimated $18.2M sold.
Based on aggregated 13F filings for Q3 2022.